Illumina, Inc. ILMN recently announced that it collaborated with QIAGEN N.V. QGEN to expand the availability and use of NGS-based In-Vitro Diagnostic (“IVD”) test kits, including companion ...

Illumina founded the company in 2016, using its next-generation sequencing technology to develop data science and machine learning for early cancer detection, eventually raising $2 billion in ...

Genomics pioneer Illumina announced Monday it has acquired a San Diego startup that makes a specialized processor to speed the analysis of genetic data.

Driven by the need for a tool to address African genomic diversity, Illumina was selected to develop an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa ...

To enhance the power of TruSeq Custom Enrichment kits, Illumina is also releasing DesignStudio - an online tool that simplifies the design and ordering of custom capture probes for targeted ...

Illumina today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.

SEOUL, South Korea-- (BUSINESS WIRE)--On June 23, 2020, Illumina, a global leader in DNA sequencing and array-based technologies, announced it has received regulatory approval from South Korea’s ...

Omniome, a San Diego sequencing firm founded in 2013, will be acquired for up to $800 million by Bay Area company Pacific Biosciences, a rival of Illumina.

Illumina, Inc. today announced TruSeq sample preparation kits for DNA, RNA, and small RNA applications and the TruSeq Exome Enrichment Kit, for use across the company's portfolio of sequencing ...

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell system alongside a ...